Protrka Zoran, Arsenijević Slobodan, Arsenijević Petar, Mitrović Slobodanka, Stanković Vesna, Milosavljević Miloš, Nedović Jasmina, Kastratović Tatjana, Durić Janko
Department of Obstetrics and Gynaecology, University of Kragujevac, Serbia.
Med Glas (Zenica). 2012 Aug;9(2):248-55.
To establish the role of co-overexpression of bcl-2 and cerbB- 2/neu protooncogenes in uterine cervix carcinogenesis, we examined 138 tissue samples of low grade cervical squamous intraepithelial lesions (SIL), high grade SIL, cervical carcinoma in situ and cervical invasive carcinoma, stage IA-IIA (study group) and 36 samples without SIL or malignancy (control group).
The expression of bcl-2 and c-erbB-2/neu was detected immunohistochemically using a monoclonal antibody. Fisher's exact test (p less than 0.05) was used to assess statistical significance.
Co-overexpression of Bcl-2 and c-erbB-2/neu was found to increase in direct relation to the grade of the squamose intraepitelial lesions (SIL) of cervix. Statistically significant difference was found in the frequency of co-overexpression in patients with high grade SIL (12/22, p=0.006), cervical carcinoma in situ (10/22, p=0.018) and cervical invasive carcinoma (12/26, p=0.012), in relation to the control group. High sensitivity was of great diagnostic significance for the detection of these types of changes in the uterine cervix.
On the basis of high predictive values it can be said that in patients with co-overexpression of bcl-2 and c-erbB-2/neu overexpression there is a great possibility that they have premalignant or malignant changes in the uterine cervix. However, a more extensive series of samples and additional tests are required to establish the prognostic significance of these oncogenes in cervical carcinogenesis.
为了确定bcl-2和cerbB-2/neu原癌基因共同过表达在子宫颈癌发生中的作用，我们检测了138例低级别宫颈鳞状上皮内病变（SIL）、高级别SIL、宫颈原位癌和宫颈浸润癌（IA-IIA期）的组织样本（研究组）以及36例无SIL或恶性病变的样本（对照组）。
使用单克隆抗体通过免疫组织化学法检测bcl-2和c-erbB-2/neu的表达。采用Fisher精确检验（p<0.05）评估统计学意义。
发现Bcl-2和c-erbB-2/neu的共同过表达与宫颈鳞状上皮内病变（SIL）的级别直接相关。与对照组相比，高级别SIL患者（12/22，p=0.006）、宫颈原位癌患者（10/22，p=0.018）和宫颈浸润癌患者（12/26，p=0.012）中共同过表达的频率存在统计学显著差异。高敏感性对于检测子宫颈的这些类型变化具有重要诊断意义。
基于高预测价值，可以说bcl-2和c-erbB-2/neu共同过表达的患者子宫颈很有可能发生了癌前或恶性变化。然而，需要更广泛的样本系列和额外的检测来确定这些癌基因在子宫颈癌发生中的预后意义。
